Repros Therapeutics reports superior results By: MarketMinute.com Stock News August 28, 2014 at 17:10 PM EDT Repros Therapeutics Inc. (Nasdaq: RPRX) reported superior results for its Androxal in treating hypogonadism sending the stock price soaring $3.37 to close at $21.58.